Shared Decision-Making on Using a CDK4/6 Inhibitor plus an Aromatase Inhibitor for HR+/HER2− Metastatic Breast Cancer: A Podcast

Abstract

Abstract Shared decision-making involves patients engaging with their physicians to make informed decisions regarding treatment selection, a process that empowers patients and ensures that treatment decisions reflect their individual values and preferences. However, shared decision-making can be challenging to implement for various reasons, including time, staffing, or resource limitations at community practices and differences in patients’ cultural backgrounds or health literacy. In this podcast, we discuss how to ensure that individual patients’ needs and concerns are addressed, including an overview of different approaches for initial consultations, strategies for tailoring conversations based on a patient’s background or health literacy, and trustworthy resources that can help improve patients’ understanding. As an illustrative example, we focus on how to implement shared decision-making to address the needs of a patient with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer who is eligible for combination therapy with a cyclin-dependent kinase 4/6 inhibitor plus an aromatase inhibitor. Overall, this podcast illustrates how shared decision-making is an achievable goal, even in small or underresourced practices, and provides an instructive guide on how to facilitate shared decision-making for patients with HR+/HER2− metastatic breast cancer. Podcast Discussion (MP4 29880 KB) Infographic

Keywords

• Cyclin-dependent kinase 4/6 inhibitor
• HR+/HER2− metastatic breast cancer
• Shared decision-making